Investigation of pathways regulating cell survival and early antiangiogenic response to single agent Everolimus or Rapamycin in renal cancer.
Phase of Trial: Phase IV
Latest Information Update: 15 Nov 2012
At a glance
- Drugs Everolimus (Primary) ; Sirolimus (Primary)
- Indications Renal cancer
- Focus Pharmacodynamics; Therapeutic Use
- 25 Feb 2012 Planned end date changed from 22 Sep 2013 to 22 Mar 2015 as reported by EudraCT.
- 25 Feb 2012 Investigational drug 'Everolimus' identified as reported by EudraCT.
- 25 Feb 2012 Official title amended as reported by EudraCT.